Filing summary
Entity identification: The supplied filing is Homology Medicines, Inc.’s Form 10-Q, not a filing identified as Q32 Bio Inc. Investors should verify the company and filing match their intended review.
Business context and reporting period
Unaudited results cover the three months ended March 31, 2018, with balance-sheet comparisons to December 31, 2017 and operating results compared with Q1 2017. Homology Medicines was a preclinical-stage genetic medicines company developing gene therapy and nuclease-free gene editing for rare diseases. Its lead candidate, HMI-102, was in preclinical development for phenylketonuria (PKU); the company had not filed an IND or generated product-sales revenue.
Key financial metrics
| Metric | Q1 2018 / March 31, 2018 | Comparable period / prior balance |
|---|---|---|
| Collaboration revenue | $0.82 million | $0 in Q1 2017 |
| Research and development expense | $8.00 million | $2.80 million in Q1 2017 |
| General and administrative expense | $3.83 million | $1.89 million in Q1 2017 |
| Total operating expenses | $11.83 million | $4.69 million in Q1 2017 |
| Operating loss | $11.00 million | $4.69 million in Q1 2017 |
| Net loss | $10.52 million | $5.55 million in Q1 2017 |
| Net loss per common share, basic and diluted | $4.21 | $2.79 in Q1 2017 |
| Net cash used in operating activities | $11.04 million | $4.52 million in Q1 2017 |
| Cash and cash equivalents | $46.21 million | $51.57 million at December 31, 2017 |
| Short-term investments | $70.52 million | $78.08 million at December 31, 2017 |
| Total assets | $129.08 million | $137.53 million at December 31, 2017 |
| Total liabilities | $40.84 million | $39.22 million at December 31, 2017 |
| Debt | None reported | None reported at December 31, 2017 |
Cash, cash equivalents and short-term investments totaled $116.73 million at March 31, 2018. The company reported $9.44 million of current liabilities and $111.0 million of working capital. Collaboration revenue was recognized under the Novartis agreement; no product revenue was reported. Profit margins are not meaningful for this loss-making, preclinical business.
Material changes versus Q1 2017
- Operating expenses rose $7.13 million, including a $5.20 million increase in R&D and a $1.94 million increase in G&A. Management attributed R&D growth mainly to HMI-102 external development and manufacturing costs, increased headcount, and other preclinical work.
- Net loss increased by $4.97 million. Higher interest income partly offset the larger operating loss; Q1 2017 also included a $0.88 million expense from remeasurement of a preferred-stock tranche liability, with no such expense in Q1 2018.
- Operating cash use increased to $11.04 million from $4.52 million. Investing activities provided $6.64 million in Q1 2018, mainly reflecting net maturities of short-term investments, while financing used $0.96 million, largely for deferred IPO costs.
- Revenue began in Q1 2018 as the company recognized a portion of Novartis upfront consideration; $33.3 million remained recorded as deferred revenue at March 31.
Outlook, commentary, risks and unusual items
- Management expected to initiate an HMI-102 Phase 1/2 trial in 2019 and receive initial clinical data in 2019, and expected to nominate a lead PKU gene-editing candidate in 2018. These are forward-looking plans, not achieved outcomes.
- Management projected existing cash resources, including subsequent IPO proceeds, would fund operations for at least two years. It also expected operating expenses and capital expenditures to increase; estimated facility buildout and equipment expenditures at approximately $20–22 million during 2018 and the first half of 2019.
- On April 2, 2018, after quarter-end, the company completed its IPO, issuing 10.35 million shares at $16.00 per share for approximately $151.0 million in net proceeds. Preferred shares converted into 24,168,656 common shares. These proceeds are not included in the March 31 balance sheet.
- The Novartis collaboration covered ophthalmic targets and sickle cell disease. Potential payments include up to $960 million in milestones and tiered royalties, but these are contingent and not assured. Novartis may select up to four targets; the agreement includes research, development, manufacturing and commercialization arrangements.
- Key risks include clinical and regulatory uncertainty, gene-therapy safety and off-target risks, manufacturing scale-up and supplier dependence, reliance on intellectual property and licenses, future financing needs, and the possibility that HMI-102 or other candidates fail to demonstrate safety or efficacy. The company said it expected continued losses and negative operating cash flows.
- The filing reported no material legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls as of March 31, 2018. It disclosed $28.37 million in future minimum lease payments and a new long-term facility lease.
Most important facts for investors to verify
- Confirm the intended issuer: the supplied filing names Homology Medicines, Inc., while the request metadata names Q32 Bio Inc.
- Verify the post-quarter IPO proceeds, share issuance and preferred-stock conversion in the company’s subsequent filings and current capitalization information.
- Track HMI-102 IND submission, trial initiation and data timing, as well as progress toward the planned gene-editing candidate nomination.
- Assess cash burn, facility construction spending and whether management’s stated two-year funding runway remains valid under updated spending and development assumptions.
- Review Novartis collaboration milestones, target selections, termination provisions and the accounting assumptions supporting deferred revenue recognition.